Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 20/20 | 0.64 |
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23860111 | 0.89 | DRD4 (0.66) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL7371617 | 0.86 | DRD4 (0.76) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL4315640 | 0.83 | DRD4 (0.72) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL5695486 | 0.80 | DRD4 (0.71) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL352001 | 0.80 | DRD4 (0.71) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL1877824 | 0.80 | DRD4 (0.71) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL7366679 | 0.80 | DRD4 (0.63) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL27645338 | 0.79 | DRD4 (0.66) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL9385194 | 0.79 | DRD4 (0.78) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL11973909 | 0.78 | DRD4 (0.76) | DRD4DRD2DRD3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | DRD4 3776/4885DRD2 2785/4885DRD3 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.